Berlin, Germany - Two separate groups of researchers have reported cases in which patients with recalcitrant adult-onset Still's disease (AOSD) showed a prompt response to treatment with the ...

Findings showed that 53.8% of patients treated with emapalumab achieved a complete response. The Food and Drug Administration (FDA) has approved Gamifant ® (emapalumab-lzsg) for the treatment of adult ...

Adult-onset Still's disease (AOSD) is a rare inflammatory disorder. Thanks to a new initiative, AOSD is now considered to be the adult counterpart of systemic juvenile idiopathic arthritis, but in ...

Adult-onset Still’s disease (AOSD) is a rare, systemic autoinflammatory disorder characterised by high spiking fevers, an evanescent rash, and joint involvement. Its clinical spectrum is diverse, ...

Adult Still’s Disease (ASD) is a rare, systemic, autoinflammatory disorder of unknown etiology. It is characterized by high-grade spiking fevers, arthritis, systemic inflammation, and a typical ...